Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
373 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00269828 | A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.(PIONEER) | terminated | Phase 3 | 600 | CTI BioPharmaINDUSTRY | 11 | Nov 24, 2020 | clinicaltrials |
| NCT01076010 | An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). | completed | Phase 3 | 277 | AVEO Pharmaceuticals, Inc.INDUSTRY | 15 | Oct 5, 2020 |
| clinicaltrials |
| NCT00625898 | BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab(BETH) | terminated | Phase 3 | 3,509 | NSABP Foundation IncNETWORK | 40 | Sep 10, 2020 | clinicaltrials |
| NCT02395172 | Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) | completed | Phase 3 | 792 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 29 | Aug 3, 2020 | clinicaltrials |
| NCT02718417 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | terminated | Phase 3 | 998 | PfizerINDUSTRY | 25 | Jul 14, 2020 | clinicaltrials |
| NCT00337103 | E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | completed | Phase 3 | 1,276 | Eisai Inc.INDUSTRY | 23 | Jun 18, 2020 | clinicaltrials |
| NCT00824265 | Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia | completed | Phase 3 | 365 | Novartis PharmaceuticalsINDUSTRY | 18 | Jun 18, 2020 | clinicaltrials |
| NCT00088530 | BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | completed | Phase 3 | 140 | CTI BioPharmaINDUSTRY | 20 | Feb 5, 2020 | clinicaltrials |
| NCT02272413 | Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer | completed | Phase 3 | 671 | Boehringer IngelheimINDUSTRY | 28 | Jan 13, 2020 | clinicaltrials |
| NCT00600340 | 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab(TURANDOT) | completed | Phase 3 | 564 | Central European Cooperative Oncology GroupOTHER | 12 | Dec 30, 2019 | clinicaltrials |
| NCT02354508 | Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues | completed | Phase 3 | 123 | Novartis PharmaceuticalsINDUSTRY | 15 | Dec 10, 2019 | clinicaltrials |
| NCT01715129 | Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer(DKP 3M SC) | completed | Phase 3 | 126 | IpsenINDUSTRY | 5 | Dec 9, 2019 | clinicaltrials |
| NCT00452569 | Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma(OPTIMUM) | completed | Phase 3 | 499 | CelgeneINDUSTRY | 15 | Nov 18, 2019 | clinicaltrials |
| NCT00547651 | AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy | completed | Phase 3 | 637 | CelgeneINDUSTRY | 17 | Nov 6, 2019 | clinicaltrials |
| NCT00472303 | A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine | completed | Phase 3 | 622 | Grünenthal GmbHINDUSTRY | 16 | Nov 4, 2019 | clinicaltrials |
| NCT01264887 | Tapentadol in Chronic Malignant Tumour Related Pain | terminated | Phase 3 | 31 | Grünenthal GmbHINDUSTRY | 7 | Nov 4, 2019 | clinicaltrials |
| NCT01030783 | A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma(TIVO-1) | completed | Phase 3 | 517 | AVEO Pharmaceuticals, Inc.INDUSTRY | 16 | Oct 28, 2019 | clinicaltrials |
| NCT01170663 | A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma(RAINBOW) | completed | Phase 3 | 665 | Eli Lilly and CompanyINDUSTRY | 26 | Sep 18, 2019 | clinicaltrials |
| NCT00191126 | Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC | completed | Phase 3 | 263 | Eli Lilly and CompanyINDUSTRY | 15 | Sep 12, 2019 | clinicaltrials |
| NCT02555878 | A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants | completed | Phase 3 | 841 | Janssen Research & Development, LLCINDUSTRY | 10 | Sep 12, 2019 | clinicaltrials |
| NCT02187367 | Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients(EGF) | terminated | Phase 3 | 106 | Bioven EuropeINDUSTRY | 11 | Sep 10, 2019 | clinicaltrials |
| NCT02402712 | Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer | completed | Phase 3 | 418 | Hoffmann-La RocheINDUSTRY | 12 | Sep 6, 2019 | clinicaltrials |
| NCT01818752 | Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma(CLARION) | completed | Phase 3 | 955 | AmgenINDUSTRY | 30 | Aug 26, 2019 | clinicaltrials |
| NCT01901146 | Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer(Lilac) | completed | Phase 3 | 725 | AmgenINDUSTRY | 18 | Aug 7, 2019 | clinicaltrials |
| NCT02292446 | Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. | completed | Phase 3 | 161 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 18, 2019 | clinicaltrials |
| NCT00910910 | Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)(ORIGIN) | completed | Phase 3 | 450 | CelgeneINDUSTRY | 27 | Jul 9, 2019 | clinicaltrials |
| NCT00901901 | Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma(SEARCH) | completed | Phase 3 | 732 | BayerINDUSTRY | 26 | May 30, 2019 | clinicaltrials |
| NCT02364999 | A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC | completed | Phase 3 | 719 | PfizerINDUSTRY | 27 | Feb 7, 2019 | clinicaltrials |
| NCT01633060 | A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi(BELLE-3) | terminated | Phase 3 | 432 | Novartis PharmaceuticalsINDUSTRY | 22 | Jan 30, 2019 | clinicaltrials |
| NCT00805194 | LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer | completed | Phase 3 | 1,314 | Boehringer IngelheimINDUSTRY | 27 | Dec 5, 2018 | clinicaltrials |
| NCT01200758 | A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma | completed | Phase 3 | 410 | Hoffmann-La RocheINDUSTRY | 30 | Nov 27, 2018 | clinicaltrials |
| NCT01313689 | Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | completed | Phase 3 | 122 | Novartis PharmaceuticalsINDUSTRY | 17 | Nov 8, 2018 | clinicaltrials |
| NCT01010061 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT01998880 | CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT02053610 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT00984282 | Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer | completed | Phase 3 | 417 | BayerINDUSTRY | 18 | Sep 13, 2018 | clinicaltrials |
| NCT00692770 | Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)(STORM) | completed | Phase 3 | 1,114 | BayerINDUSTRY | 28 | Aug 8, 2018 | clinicaltrials |
| NCT01482962 | Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma | completed | Phase 3 | 271 | Millennium Pharmaceuticals, Inc.INDUSTRY | 31 | Jul 31, 2018 | clinicaltrials |
| NCT01767155 | Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer(ZoptEC) | completed | Phase 3 | 511 | AEterna ZentarisINDUSTRY | 22 | Jul 31, 2018 | clinicaltrials |
| NCT02557035 | An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting | completed | Phase 3 | 441 | Helsinn Healthcare SAINDUSTRY | 9 | Jun 20, 2018 | clinicaltrials |
| NCT01200589 | Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy(HOMER) | terminated | Phase 3 | 438 | Novartis PharmaceuticalsINDUSTRY | 16 | May 16, 2018 | clinicaltrials |
| NCT01262651 | Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer | completed | Phase 3 | 397 | GW Pharmaceuticals LtdINDUSTRY | 12 | Apr 23, 2018 | clinicaltrials |
| NCT00338286 | A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy | completed | Phase 3 | 2,098 | Janssen Research & Development, LLCINDUSTRY | 21 | Mar 19, 2018 | clinicaltrials |
| NCT00601172 | A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting. | completed | Phase 3 | 710 | GlaxoSmithKlineINDUSTRY | 11 | Jan 17, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials